<pmc-articleset xmlns:ns0="http://www.w3.org/1999/xlink">
<article article-type="research-article" xml:lang="en" dtd-version="1.4">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Adv Anat Pathol</journal-id>
<journal-id journal-id-type="iso-abbrev">Adv Anat Pathol</journal-id>
<journal-id journal-id-type="pmc-domain-id">319</journal-id>
<journal-id journal-id-type="pmc-domain">nihpa</journal-id>
<journal-title-group>
<journal-title>Advances in anatomic pathology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1072-4109</issn>
<issn pub-type="epub">1533-4031</issn>
<custom-meta-group>
<custom-meta>
<meta-name>pmc-is-collection-domain</meta-name>
<meta-value>yes</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-collection-title</meta-name>
<meta-value>NIHPA Author Manuscripts</meta-value>
</custom-meta>
</custom-meta-group>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmcid">PMC7700753</article-id>
<article-id pub-id-type="pmcid-ver">PMC7700753.1</article-id>
<article-id pub-id-type="pmcaid">7700753</article-id>
<article-id pub-id-type="pmcaiid">7700753</article-id>
<article-id pub-id-type="manuscript-id">NIHMS1644989</article-id>
<article-id pub-id-type="pmid">32205473</article-id>
<article-id pub-id-type="doi">10.1097/PAP.0000000000000256</article-id>
<article-id pub-id-type="manuscript-id-alternative">NIHMS1644989</article-id>
<article-id pub-id-type="manuscript-id-alternative">NIHPA1644989</article-id>
<article-version article-version-type="pmc-version">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name name-style="western">
<surname>Bellizzi</surname>
<given-names initials="AM">Andrew M</given-names>
</name>
<degrees>M.D.</degrees>
<aff id="A1">Department of Pathology, University of Iowa Hospitals and Clinics, University of Iowa Carver College of Medicine, Iowa City, IA</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="CR1">Address reprint requests to: Andrew M Bellizzi, M.D., University of Iowa Hospitals and Clinics, Department of Pathology, 200 Hawkins Drive, Iowa City, IA 52242, phone: 319-356-4436, fax: 319-384-8053, <email>andrew-bellizzi@uiowa.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>5</month>
<year>2020</year>
</pub-date>
<volume>27</volume>
<issue>3</issue>
<issue-id pub-id-type="pmc-issue-id">369721</issue-id>
<fpage>114</fpage>
<lpage>163</lpage>
<pub-history>
<event event-type="nihms-submitted">
<date>
<day>11</day>
<month>11</month>
<year>2020</year>
</date>
</event>
<event event-type="pmc-release">
<date>
<day>29</day>
<month>11</month>
<year>2020</year>
</date>
</event>
<event event-type="pmc-live">
<date>
<day>29</day>
<month>11</month>
<year>2020</year>
</date>
</event>
<event event-type="pmc-last-change">
<date iso-8601-date="2024-06-16 21:25:30.187">
<day>16</day>
<month>06</month>
<year>2024</year>
</date>
</event>
</pub-history>
<self-uri content-type="pmc-pdf" ns0:href="nihms-1644989.pdf" />
<abstract id="ABS1">
<p id="P1">Immunohistochemistry represents an indispensable complement to an epidemiology and morphology-driven approach to tumor diagnosis and site of origin assignment. This review reflects the state of my current practice, based on 15-years’ experience in Pathology and a deep-dive into the literature, always striving to be better equipped to answer the age old questions, “What is it, and where is it from?” The tables and figures in this manuscript are the ones I “pull up on the computer” when I’m teaching at the microscope and turn to myself when I’m (frequently) stuck. This field is so exciting because I firmly believe that, through the application of next-generation immunohistochemistry, we can provide better answers than ever before. Specific topics covered in this review include 1. broad tumor classification and associated screening markers; 2. the role of cancer epidemiology in determining pretest probability; 3. broad-spectrum epithelial markers; 4. non-canonical expression of broad tumor class screening markers; 5. a morphologic pattern-based approach to poorly to undifferentiated malignant neoplasms; 6. a morphologic and immunohistochemical approach to define 4 main carcinoma types; 7. CK7/CK20 coordinate expression; 8. added value of semiquantitative immunohistochemical stain assessment; algorithmic immunohistochemical approaches to 9. “garden variety” adenocarcinomas presenting in the liver, 10. large polygonal cell adenocarcinomas, 11. the distinction of primary surface ovarian epithelial tumors with mucinous features from metastasis, 12. tumors presenting at alternative anatomic sites, 13. squamous cell carcinoma vs. urothelial carcinoma, and neuroendocrine neoplasms, including 14. the distinction of pheochromocytoma/paraganglioma from well-differentiated neuroendocrine tumor, site of origin assignment in 15. well-differentiated neuroendocrine tumor and 16. poorly differentiated neuroendocrine carcinoma, and 17. the distinction of well-differentiated neuroendocrine tumor G3 from poorly differentiated neuroendocrine carcinoma; it concludes with 18. a discussion of diagnostic considerations in the broad-spectrum keratin/CD45/S-100-“triple-negative” neoplasm.</p>
</abstract>
<kwd-group>
<kwd>immunohistochemistry</kwd>
<kwd>tumor classification</kwd>
<kwd>carcinoma of unknown primary</kwd>
<kwd>site of origin</kwd>
<kwd>differential diagnosis</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>pmc-status-qastatus</meta-name>
<meta-value>0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-status-live</meta-name>
<meta-value>yes</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-status-embargo</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-status-released</meta-name>
<meta-value>yes</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-open-access</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-olf</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-manuscript</meta-name>
<meta-value>yes</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-legally-suppressed</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-has-pdf</meta-name>
<meta-value>yes</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-has-supplement</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-pdf-only</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-suppress-copyright</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-is-real-version</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-is-scanned-article</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-preprint</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-in-epmc</meta-name>
<meta-value>yes</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
</article>
</pmc-articleset>